The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.
Clinics and health plans are expanding telehealth services as increased immigration enforcement has coincided with some patients, including immigrant families, delaying or avoiding in-person medical visits.
Large-scale genetic analyses identify multiple susceptibility loci for Takayasu arteritis, confirming HLA-B*52 as the strongest association and revealing immune pathways that vary by ancestry.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Research has shown that patients of color prefer seeing doctors of their own race — and some studies have shown health outcomes are better for Black patients seeing Black doctors.